DE3782576D1 - Morphologisch homogene formen von famotidin und verfahren zu deren herstellung. - Google Patents

Morphologisch homogene formen von famotidin und verfahren zu deren herstellung.

Info

Publication number
DE3782576D1
DE3782576D1 DE8787306882T DE3782576T DE3782576D1 DE 3782576 D1 DE3782576 D1 DE 3782576D1 DE 8787306882 T DE8787306882 T DE 8787306882T DE 3782576 T DE3782576 T DE 3782576T DE 3782576 D1 DE3782576 D1 DE 3782576D1
Authority
DE
Germany
Prior art keywords
famotidine
production
homogeneous forms
morphologically homogeneous
morphologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787306882T
Other languages
English (en)
Other versions
DE3782576T2 (de
DE3782576T3 (de
Inventor
Peter Bod
Kalman Harsanyi
Bela Hegedus
Erik Bogsch
Eva Fekecs
Imre Peter
Zsuzsanna Aracs
Sandor Miszori
Maria Stiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10963778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3782576(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Publication of DE3782576D1 publication Critical patent/DE3782576D1/de
Publication of DE3782576T2 publication Critical patent/DE3782576T2/de
Application granted granted Critical
Publication of DE3782576T3 publication Critical patent/DE3782576T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE3782576T 1986-08-05 1987-08-04 Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung. Expired - Lifetime DE3782576T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU863370A HU196775B (en) 1986-08-05 1986-08-05 Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances

Publications (3)

Publication Number Publication Date
DE3782576D1 true DE3782576D1 (de) 1992-12-17
DE3782576T2 DE3782576T2 (de) 1993-03-25
DE3782576T3 DE3782576T3 (de) 2002-08-08

Family

ID=10963778

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3782576T Expired - Lifetime DE3782576T3 (de) 1986-08-05 1987-08-04 Morphologisch homogene Formen von Famotidin und Verfahren zu deren Herstellung.
DE198787306882T Pending DE256747T1 (de) 1986-08-05 1987-08-04 Morphologisch homogene formen von famotidine und verfahren zu deren herstellung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE198787306882T Pending DE256747T1 (de) 1986-08-05 1987-08-04 Morphologisch homogene formen von famotidine und verfahren zu deren herstellung.

Country Status (18)

Country Link
US (3) US4894459A (de)
EP (1) EP0256747B2 (de)
JP (2) JP2644234B2 (de)
KR (1) KR940003954B1 (de)
CN (1) CN1024275C (de)
AR (1) AR243175A1 (de)
AT (1) ATE82274T1 (de)
AU (1) AU604040B2 (de)
BG (1) BG60496B2 (de)
CA (1) CA1265809A (de)
CS (1) CS268188B2 (de)
DE (2) DE3782576T3 (de)
DK (1) DK175022B1 (de)
FI (1) FI89917C (de)
GR (1) GR871216B (de)
HU (1) HU196775B (de)
PH (1) PH24069A (de)
PT (1) PT85473B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86330A0 (en) * 1987-06-22 1988-11-15 Marga Investigacion Famotidine polymorphic forms and their preparation
CA2166891C (en) * 1993-07-09 2001-07-03 Sang K. Wong Method for making freeze dried drug dosage forms
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
TWI353979B (en) * 2002-04-10 2011-12-11 Nippon Zoki Pharmaceutical Co Novel crystal form of 5-hydroxy-1-methylhydantoin
CA2426122A1 (en) * 2002-05-02 2003-11-02 M/S Tonira Pharma Limited A process for the preparation of a combination of famotidine polymorphis a and b
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
JP4739760B2 (ja) * 2002-12-11 2011-08-03 タロー・ファーマシューティカル・インダストリーズ・リミテッド バルビツール酸誘導体を使用する運動障害の治療方法
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
EP1781624A4 (de) * 2004-07-02 2010-06-23 Taro Pharma Ind Verfahren zur herstellung von 1-methoxymethyl-5,5-diphenylbarbitursäure
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
NZ565846A (en) * 2005-07-18 2011-12-22 Horizon Therapeutics Inc Medicaments containing famotidine and ibuprofen and administration of same
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
CA2657928C (en) 2006-07-18 2014-12-02 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20100297224A1 (en) * 2006-08-31 2010-11-25 Horizon Therapeutics, Inc. NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US20080132529A1 (en) * 2006-11-14 2008-06-05 Avraham Yacobi Method of improving bioavailability for non-sedating barbiturates
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
WO2022015784A1 (en) 2020-07-15 2022-01-20 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1543238A (en) * 1976-09-21 1979-03-28 Smith Kline French Lab Polymorph of cimetidine
JPS6056143B2 (ja) * 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
JPS5655383A (en) * 1979-10-12 1981-05-15 Yamanouchi Pharmaceut Co Ltd Amizine derivative and its preparation
HU185457B (en) * 1981-09-25 1985-02-28 Richter Gedeon Vegyeszet Process for preparating cimetidine-z
US4496737A (en) * 1982-09-27 1985-01-29 Merck & Co., Inc. Process for preparing sulfamylamidine antisecretory agents
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
HU194845B (en) * 1985-09-11 1988-03-28 Richter Gedeon Vegyeszet Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin
DE3644246A1 (de) * 1986-06-20 1987-12-23 Uriach & Cia Sa J Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
IL86330A0 (en) * 1987-06-22 1988-11-15 Marga Investigacion Famotidine polymorphic forms and their preparation

Also Published As

Publication number Publication date
AU7654287A (en) 1988-02-11
DK175022B1 (da) 2004-04-26
JP2708715B2 (ja) 1998-02-04
FI89917C (fi) 1993-12-10
FI89917B (fi) 1993-08-31
EP0256747B1 (de) 1992-11-11
CS268188B2 (en) 1990-03-14
AU604040B2 (en) 1990-12-06
DK404187A (da) 1988-02-06
DE256747T1 (de) 1988-11-24
AR243175A1 (es) 1993-07-30
HU196775B (en) 1989-01-30
FI873346A0 (fi) 1987-08-03
JPH07316141A (ja) 1995-12-05
ATE82274T1 (de) 1992-11-15
GR871216B (en) 1987-11-19
EP0256747A1 (de) 1988-02-24
US5128477A (en) 1992-07-07
PT85473B (pt) 1990-06-29
PH24069A (en) 1990-03-05
PT85473A (en) 1987-09-01
CN1024275C (zh) 1994-04-20
EP0256747B2 (de) 2001-11-28
BG60496B2 (bg) 1995-05-31
CS579987A2 (en) 1989-04-14
JP2644234B2 (ja) 1997-08-25
DE3782576T2 (de) 1993-03-25
US4894459A (en) 1990-01-16
CA1265809A (en) 1990-02-13
HUT45240A (en) 1988-06-28
KR940003954B1 (ko) 1994-05-09
FI873346A (fi) 1988-02-06
CN87105373A (zh) 1988-06-08
JPS6399065A (ja) 1988-04-30
DE3782576T3 (de) 2002-08-08
KR880002847A (ko) 1988-05-11
DK404187D0 (da) 1987-08-03
US5120850A (en) 1992-06-09

Similar Documents

Publication Publication Date Title
DE3782576D1 (de) Morphologisch homogene formen von famotidin und verfahren zu deren herstellung.
DE3887625D1 (de) Verfahren zur Herstellung von 1,1,1-Trifluorodichlorethan und von 1,1,1,2-Tetrafluorchlorethan.
DE3784612D1 (de) Thermistor und verfahren zu seiner herstellung.
DE3770675D1 (de) Trockenuebertragungsmaterial von musterungen und verfahren zu seiner herstellung.
DE3783007D1 (de) 9-alpha-hydroxysteroide, verfahren zu ihrer herstellung und verfahren zur herstellung der entsprechenden 9(11)-dehydro-derivate.
DE3780560D1 (de) Fuehler und verfahren zu dessen herstellung.
DE3751243D1 (de) Opto-elektronisches Bauelement und Verfahren zu seiner Herstellung.
DE3785163D1 (de) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-en-2-carbonsaeurederivate und verfahren zu deren herstellung.
DE3789881D1 (de) Verfahren zur Herstellung von Photomasken und Photomaske.
DE3780532D1 (de) Amphoterische staerke und verfahren zu deren herstellung.
DE3874372D1 (de) Polysiloxan-polyimide und verfahren zu deren herstellung.
DE68927949D1 (de) 3,9-Diphosphaspiroundecane und Verfahren zur Herstellung von 3,9-Diphosphaspiroundecanen
DE3579641D1 (de) Verfahren und vorrichtung zur kontinuierlichen herstellung von alkoxypolysiloxanen.
DE68912655D1 (de) Verfahren zur Herstellung von Decabromediphenylalkanen und Decabromdiphenylethan.
ATE87801T1 (de) Verfahren und vorrichtung zur herstellung von reissverschluessen.
DE3789524D1 (de) Polymer-Metallverbundstoff und Verfahren zu seiner Herstellung.
DE3787543D1 (de) Verfahren zur herstellung von 6,13-dihydrochinacridonen und chinacridonen.
DE3684922D1 (de) Verfahren zur herstellung von 2-phenylbenzotriazolen und 2-phenylbenzotriazol-n-oxyden.
DE3783199D1 (de) Verfahren zur herstellung von 4,4' diaminodiphenylmethan und derivaten davon.
DE3881568D1 (de) Supraleiter und verfahren zu seiner herstellung.
DE3887445D1 (de) Verfahren zur herstellung von glukagonhomologen und deren verwendung.
DE3784185D1 (de) Mehrschichtiger mikrowellenabsorber und verfahren zu seiner herstellung.
DE3671246D1 (de) Verfahren zur herstellung von 4-androsten-3,17-dion und 1,4-androstadien-3,17-dion.
DE3685209D1 (de) Urease und verfahren zu deren herstellung.
DE59004582D1 (de) 1,3-Di-arylmethoxy-4,6-dinitrobenzole, Verfahren zu ihrer Herstellung und Verfahren zur Herstellung von 4,6-Diaminoresorcin.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings